AyurvedNews.com

NEW DELHI: The government is planning to set up an export inspection agency for Ayurveda, Unani and Siddha (Ayush) products to put an end to frequent rejection of Indian exports. There have been instances of Indian herbal exports being rejected due to metal toxicity and microbial contamination. China is a dominant player in the global herbal drug market.

The government has also proposed three levels of inspection. The certification fee for level 1 and level 2 is 0.4% and 0.2%, respectively, of the freight on board (FOB), which roughly represent the cost of the export consignment. The fee for the third level has not been finalised.

Pharmaceuticals export promotion council (Pharmexcil) has asked the government not to levy any fee or additional inspection on Ayush products. Pharmexcil chairman DB Mody told ET the industry is grappling with the problems of rupee appreciation and any additional burden would adversely impact Ayush exports.

Read the full article at source: The Economic Times

Share This

For the first time, an ayurvedic drug, Liv-52, has become the top selling drug in the country in value terms. Himalaya Healthcare’s flagship liver tonic has registered the highest sales by value, toppling traditional chemical-based best-sellers of domestic and global pharma majors, if one goes by figures available for July 2007.

According to research firm ORG IMS’ sales figures for July 2007, Liv-52 outsmarted traditional market leaders such as Pfizer’s Corex, Nicholas Piramal’s Phensedyl and last month’s best-seller Novartis’ pain-killer drug Voveran to emerge as the topper. Ayurveda-based drugs are nowhere in the top pharma sales index, and Liv-52 is the lone representation in the country’s Top 30 drugs list.

Read the full article at source: The Economic Times

Share This